Observational studyCanadian journal of psychiatry. Revue canadienne de psychiatrie2022
Generalized Anxiety Disorder 7-Item (GAD-7) Scores in Medically Authorized Cannabis Patients-Ontario and Alberta, Canada.
Observational study in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Integrated palliative care improves the quality of life of advanced cancer patients.BMC palliative care · 2025Trial
- Comprehensive evaluation of Medtronic's Butterfly platform, a new audiovisual information material for patient education and shared decision-making in surgical thyroid disease.BMC medical informatics and decision making · 2026Article
- Relationship between depression, anxiety and emotional exhaustion among infectious disease nurses: a network analysis.BMC psychiatry · 2026Article
- Caregiver health literacy in head and neck cancer and its relationship with caregiver and patient psychological distress.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Promoting recovery and prevention simultaneously through peer providers to reduce the impact of childhood sexual abuse: Acceptability, feasibility, and fidelity of an integrated intervention model.Psychotherapy (Chicago, Ill.) · 2025Article
- Based on real-world data: Risk factors and prediction model for mental disorders induced by rabies vaccination.World journal of psychiatry · 2025Article
- Alcohol use and its relation with demographic, environmental, and psychological factors among adolescents in Nabawan, Sabah.Korean journal of family medicine · 2025Article
- Complex associations between anxiety, depression, and resilience in a college student sample: a network analysis.Frontiers in psychiatry · 2025Article
- Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case Series.Psychology research and behavior management · 2025Article
- Cultural and social factors associated with generalized anxiety disorder among adolescent mothers during the postpartum period in Malawi: a cross-sectional survey.BMC global and public health · 2024Article
- Daily associations with cannabis use and sleep quality in anxious cannabis users.Behavioral sleep medicine · 2024Article
- A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance.Neuropsychopharmacology reports · 2024Article
- Article
- Study on anxiety, depression, and sleep conditions and their interrelations among vocational college students during the COVID-19 pandemic management normalization.Frontiers in public health · 2024Article
- Prevalence and factors associated with depression and anxiety among COVID-19 survivors in Dhaka city.Frontiers in psychiatry · 2024Article
- Mental well-being and sleep quality among vocational college students in Sichuan, China during standardized COVID-19 management measures.Frontiers in public health · 2024Article
- An observational study of clinical outcome measures in patients treated with cannabis-based medicinal products on the UK Medical Cannabis Registry.Neuropsychopharmacology reports · 2023Observational
- Specifying the Efficacy of Digital Therapeutic Tools for Depression and Anxiety: Retrospective, 2-Cohort, Real-World Analysis.Journal of medical Internet research · 2023Article
- "Biomedicines · 2022Article
- Sleep quality status, anxiety, and depression status of nurses in infectious disease department.Frontiers in psychology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesDespite increasing rates of legalization of medical cannabis worldwide, the current evidence available on its effect on mental health outcomes including anxiety is of mixed results. This study assesses the effect of medical cannabis on generalized anxiety disorder 7-item (GAD-7) scores in adult patients between 2014 and 2019 in Ontario and Alberta, Canada.
methodsAn observational cohort study of adults authorized to use medical cannabis. The GAD-7 was administered at the time of the first visit to the clinic and subsequently over the follow-up time period of up to 3.2 years. Overall changes in GAD-7 scores were computed (mean change) and categorized as: no change (<1 point); improvement; or worsening-over time.
resultsA total of 37,303 patients had initial GAD-7 scores recorded and 5,075 (13.6%) patients had subsequent GAD-7 follow-up scores. The average age was 54.2 years (SD 15.7 years), 46.0% were male, and 45.6% noted anxiety symptoms at the baseline. Average GAD-7 scores were 9.11 (SD 6.6) at the baseline and after an average of 282 days of follow-up (SD 264) the average final GAD-7 score recorded was 9.04 (SD 6.6): mean change -0.23 (95% CI, -0.28 to -0.17,
conclusionsOverall, there was a statistically significant decrease in GAD-7 scores over time (in particular, in the 6-12-month period). However, this change did not meet the threshold to be considered clinically significant. Thus, we did not detect clinical improvements or detriment in GAD-7 scores in medically authorized cannabis patients. However, future well-controlled clinical trials are needed to fully examine risks or benefits associated with using medical cannabis to treat anxiety conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.